Participants with a serious adverse event following a single dose, and after 3 to 5 days · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Budesonide 15 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement (decrease in CDAI > 100 or total CDAI <= 150) ‐ 8 weeks · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI <= 150) ‐… compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
Budesonide 15 mg probably leads to lower withdrawal due to disease worsening compared with placebo (moderate certainty).
1 finding from 1 review
Corticosteroid related adverse events · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in corticosteroid related adverse events compared with placebo (moderate certainty).
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Minocycline 45 mg showed no clear difference in proportion of participants with adverse event compared with minocycline 45 mg + azelaic acid gel (low certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement · Participants with rosacea
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Participants with at least 1 adverse event (all diclofenac potassium doses, 25 mg to 100 mg) · Adults with acute pain
The intervention showed no clear difference in participants with at least 1 adverse event (all diclofenac potassium… (moderate certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) ‐ famciclovir 125 mg · participants with recurrent herpes labialis
Famciclovir showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (moderate certainty).
1 finding from 1 review
Duration of attack of recurrent herpes labialis during use of the preventative intervention ‐ famciclovir 125 mg · participants with recurrent herpes labialis
Famciclovir showed no clear difference in duration of attack of recurrent herpes labialis during use of the… compared with placebo (moderate certainty).
1 finding from 1 review
Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism
1 finding from 1 review
Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · women with hirsutism
It is very uncertain whether finasteride 5 mg to 7.5 mg changes proportion of participants who reported an adverse event compared with placebo (very low certainty).
1 finding from 1 review